ArticleBMC public health2025
Cost of respiratory syncytial virus hospitalisation in Brazilian infants: a micro-costing study from the perspective of a Brazilian tertiary public hospital, 2020-2023.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory Syncytial Virus (RSV) is the leading cause of hospitalisation for respiratory diseases among young children. Costing studies are essential for planning prevention strategies. Additional costing studies in middle-income countries (MIC) are still needed to understand the impact of hospitalisations given the high economic burden of RSV in these countries. We aimed to identify and quantify the resources required and associated costs of paediatric RSV hospitalisations at a tertiary hospital in a MIC.
methodsA retrospective micro-costing study of RSV-related hospitalisations among children under the age of one year, from January 2020 to November 2023, was conducted at a tertiary public hospital in Brazil. Only cases of RSV isolated on molecular respiratory panel tests were eligible for inclusion. The study used direct and indirect expenses to calculate the average cost (AC) per hospitalisation, AC per hospital day, and the total financial impact of RSV-related hospitalisations using the absorption model. The analysis was clustered by age group and the necessity of intensive care admission. Financial data is presented in Brazilian reais (BRL) and United States dollars using purchasing power parity (USD-PPP).
resultsAfter excluding 1,354 positive tests (i.e., individuals aged one year or older), we included 231 hospital admissions. Of these, 83.1% required intensive care support. The AC per hospitalisation was BRL$29,285.47 (USD-PPP$12,051.63), with an average length of stay of 8.51 days, equivalent to BRL$3,801.00 (USD-PPP$1,564.19) AC cost per day. A total of 1,965 hospital days were counted, resulting in the financial impact at BRL$6.76 million (USD-PPP$2.78 million) due to RSV-related hospitalisations of infants in the study period. Hospitalisation episodes with intensive care unit admission were significantly more expensive, with the higher costs concentrated in the younger group (< 2 months old).
conclusionsRSV-related hospitalisations impose a significant economic burden on this Brazilian tertiary public hospital, mainly related to bed cost per day and intensive care needs in young infants. These findings highlight the need for cost-effective RSV management and prevention strategies in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.